Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Fig. 2

Summary of stage-guided treatment selection for NSCLC. The frequency indicates the stage distribution (%) at diagnosis based on AJCC stage. Survival data is reported for adjuvant chemotherapy (stage IB-IIIA), osimertinib (stage IIA-IIIA), pembrolizumab (stage IB-IIIA), and atezolizumab (stage IIA-IIIA). Increased survival for adjuvant therapy is reported as a percentage increase in comparison to surgery or chemotherapy alone

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us